|
|
Office Locations:
|
900 Larkspur Landing Circle Suite 150
Larkspur, CA 94939
Phone: 415-877-4887
Fax: 415-567-0091
| |
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
Foresite Capital invests between $10 million and $50 million per investment in emerging healthcare companies with disruptive late-stage products with large market opportunities in therapeutics, devices, diagnostics, and services. Since inception in 2011, Foresite has invested in more than 11 transformative companies spanning therapeutics, devices and diagnostics. In April of 2014, the firm announced the closing of Foresite Capital Fund II, which was oversubscribed and closed with $300 million in capital commitments. Fund II follows Foresite Capital Fund I, a $100 million fund that closed in January 2013. Foresite Capital has $3.5 billion in assets under management.
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|
|
Name | |
| |
Title | |
|
Amelia Stoj | |
| |
CCO and Assistant General Counsel | |
Dennis D. Ryan | |
MBA, CPA | |
CFO & Managing Director | |
Dorothy Margolskee | |
MD | |
Managing Director | |
Jim Tananbaum | |
MD | |
Founder & CEO | |
Shannon Bergstedt | |
| |
Principal & Venture Partner | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
12/12/2024
|
Pleno
|
CA
|
$25,000,000
|
Series B
|
12/05/2024
|
Sollis Health
|
NY
|
$33,000,000
|
Series B
|
12/03/2024
|
Maze Therapeutics
|
CA
|
$115,000,000
|
Series D
|
11/07/2024
|
Seaport Therapeutics
|
MA
|
$225,000,000
|
Series B
|
07/29/2024
|
Spear Bio
|
MA
|
$45,000,000
|
Series A
|
07/23/2024
|
Third Arc Bio
|
MA
|
$165,000,000
|
Series A
|
07/16/2024
|
Thyme Care
|
TN
|
$95,000,000
|
Series C
|
07/11/2024
|
Element Biosciences
|
CA
|
$277,000,000
|
Series D
|
04/03/2024
|
Obsidian Therapeutics
|
MA
|
$160,500,000
|
Series C
|
03/06/2024
|
Alumis
|
CA
|
$259,000,000
|
Series C
|
|
|
|
|
|